Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Degron Therapeutics logo — Aims to become a global leader in the discovery and developm...

Degron Therapeutics

Aims to become a global leader in the discovery and development of molecular glue degraders

Founded 2021 United States San Diego, United States 27 employees Series A Total: $82.00M Biotechnology, Health Care

General Information

Company Name Degron Therapeutics
Founded Year 2021
Location United States San Diego, United States
Employees 27
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Degron Therapeutics. To contact Degron Therapeutics, visit degrontx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Degron Therapeutics compare?

A PDF of Degron Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Degron Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Degron Therapeutics

Degron Therapeutics is a biotechnology startup founded in 2021 in the United States. The company's slogan "Aims to become a global leader in the discovery and development of molecular glue degraders" highlights its ambition in the industry. Degron Therapeutics is focused on pioneering a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader (MGD) drugs. With a team of renowned executives and scientific leaders, the company is dedicated to identifying and validating disease targets, particularly those undruggable by conventional small molecule inhibitors. This effort is crucial in meeting unmet medical needs across all therapeutic areas. In December 2023, Degron Therapeutics secured a grant investment from the Asian Fund For Cancer Research, demonstrating external validation and support for its innovative approach to addressing unmet medical needs. As the company continues to advance its work in the biotechnology and healthcare industries, it stands poised to make a meaningful impact as a global leader in the discovery and development of molecular glue degraders.

Business keywords: biotech, drug discovery, molecular glue degraders, small molecule inhibitors, targeted protein degradation, therapeutics, scientific excellence, oncology, inflammation, metabolic diseases, medical innovation, pharmaceutical research, disease targets, global leader, unmet medical needs

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $40.00M 8
The Group Ventures GF Xinde GTJA Investment Group
The Group Ventures, GF Xinde +6
01 May 2026
Series A Undisclosed 1
Yipinhong Pharmaceutical
01 Dec 2025
Series A $20.00M 6
FC Capital Longmen Capital Takeda Ventures
FC Capital, Longmen Capital +4
01 Dec 2024
Grant Undisclosed 1
Asian Fund for Cancer Research
Asian Fund for Cancer Research
01 Dec 2023
Series A $22.00M 6
Baidu Ventures Cowin Venture Dyee Capital
Baidu Ventures, Cowin Venture +4
01 Jun 2022
Spinout Undisclosed 1
ShanghaiTech University
01 Jan 2021

Degron Therapeutics Alternatives & Competitors

View All Alternatives
Degron Therapeutics vs
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. United States

VCP/p97 Inhibitors for Oncology and Neurodegenerative Diseases

Series C
3 employees
Biopharma, Biotechnology
Compare Degron Therapeutics vs Cleave Therapeutics, Inc.
Degron Therapeutics vs
Sibylla Biotech
Sibylla Biotech Italy

Fold the future

Series A
41 employees
Biotechnology, Health Care
Compare Degron Therapeutics vs Sibylla Biotech
Degron Therapeutics vs
Redx Pharma
Redx Pharma United Kingdom

Biotech company focusing on the discovery and development of novel targeted medicines to treat cance...

Post-IPO Equity
39 employees
Biotechnology, Health Care
Also compare with: Degron Therapeutics vs Plexium Plexium View all alternatives

FAQ About Degron Therapeutics

Aims to become a global leader in the discovery and development of molecular glue degraders
Degron Therapeutics was founded in 2021.
Degron Therapeutics is headquartered in San Diego, United States.
Degron Therapeutics operates in Biotechnology and Health Care. Its work centres on biotech, drug discovery, molecular glue degraders and small molecule inhibitors.
Degron Therapeutics has approximately 27 employees.
Degron Therapeutics has completed 6 funding rounds, raising a total of $82.00M. The latest funding stage is Series A.
Top alternatives and competitors to Degron Therapeutics include Cleave Therapeutics, Inc., Sibylla Biotech, Redx Pharma, Plexium, Cedilla Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Degron Therapeutics and Cleave Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Degron Therapeutics, https://bouncewatch.com/company/degron-therapeutics, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout